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a b s t r a c t
Interferon-induced transmembrane (IFITM) proteins inhibit the entry of a large number of viruses. Not
surprisingly, many viruses are refractory to this inhibition. In this study, we report that different strains of HIV
and SIV are inhibited by human IFITM proteins to various degrees, with SIV of African green monkeys (SIVAGM)
being mostly restricted by human IFITM2. Interestingly, SIVAGM is as much inhibited by human IFITM2 as by
IFITM3 of its own host African green monkeys. Our data further demonstrate that the entry of SIVAGM is
impaired by human IFITM2 and that this inhibition is overcome by the cholesterol-binding compound
amphotericin B that also overcomes IFITM inhibition of inﬂuenza A viruses. These results suggest that IFITM
proteins exploit similar mechanisms to inhibit the entry of both pH-independent primate lentiviruses and the
pH-dependent inﬂuenza A viruses.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Interferon-induced transmembrane (IFITM) proteins inhibit a
wide range of viruses (reviewed in (Diamond and Farzan, 2013;
Perreira et al., 2013)). Humans have ﬁve IFITMs including IFITM1,
2, 3, 5 and 10 among which IFITM1, 2 and 3 exhibit antiviral acti-
vities (Hickford et al., 2012). These three IFITMs are ubiquitously
expressed in different tissues, and respond to type I interferon
stimulation. IFITM5 is strictly expressed in osteoblasts and has a
role in bone mineralization (Moffatt et al., 2008). The function of
IFITM10 remains unknown. Many important human pathogenic
viruses are sensitive to IFITM restriction. These include inﬂuenza A
virus, ﬂaviviruses, Ebola virus, SARS coronavirus, Rift Valley fever
virus, reovirus, human immunodeﬁciency virus type 1 (HIV-1), etc.
(Anafu et al., 2013; Brass et al., 2009; Huang et al., 2011; Jiang
et al., 2010; Lu et al., 2011; Mudhasani et al., 2013). The importance
of IFITM proteins in host antiviral defense is demonstrated by the
high mortality of iﬁtm3-knockout mice infected with inﬂuenza A
virus and by the possible association of an SNP in the human iﬁtm3
gene with the disease severity caused by inﬂuenza virus infection
(Bailey et al., 2012; Everitt et al., 2012; Wakim et al., 2013; Zhang
et al., 2013).
IFITMs are small transmembrane proteins containing 120 to
135 amino acids (Siegrist et al., 2011). IFITM2 and 3 share higher
homology as compared to IFITM1, which has a relatively shorter
N-terminal region and a longer C-terminal region. IFITM proteins
have two predicted transmembrane (TM) domains. However,
recent data suggest that only the C-terminal TM domain of IFITM3
crosses the membrane, whereas the N-terminal one serves as an
intramembrane domain (IMD) (Bailey et al., 2013; Jia et al., 2012;
Yount et al., 2012). This IMD likely associates with the cytoplasmic
leaﬂet of the lipid bilayer with the help of palmitoylated cysteine
residues (Yount et al., 2012). This type of membrane topology
allows the cytoplasmic exposure of a large portion of IFITM
sequences that may interact with cellular factors and machineries
that collectively modulate the functions of IFITMs. One example is
the 20-YEML-23 motif of IFITM3 that interacts with the adaptor
protein AP-2 and regulates IFITM3 endocytosis from the plasma
membrane en route to late endosomes (Chesarino et al., 2014; Jia
et al., 2012). The K24 residue of IFITM3 is a major site of ubiq-
uitination. This modiﬁcation affects IFITM3 subcellular localization
and antiviral activity (Yount et al., 2012).
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The IFITM proteins inhibit virus infection by impairing virus
entry (Feeley et al., 2011). Two models of inhibition have been
proposed. One model suggests that IFITM proteins interfere with
membrane hemifusion (Li et al., 2013). This model is supported by
the results that IFITM proteins suppressed cell membrane hemi-
fusion that was created by low pH at cold temperature. This
inhibition was rescued by oleic acid that promotes membrane
hemifusion (Li et al., 2013). The second model proposes that IFITM
proteins impede the formation of viral fusion pore (Desai et al.,
2014). In support of this latter model, no effect was detected on
lipid mixing between viral membrane and endosomal membrane
upon IFITM3 overexpression. Yet, the release of viral genome into
the cytoplasm was blocked by IFITM3 (Desai et al., 2014). Both
models are consistent with the notion that IFITM proteins can
modulate the biophysical property of lipid bilayer, such as mem-
brane ﬂuidity and curvature, through mechanisms that possibly
involve the interaction of IFITMs with VAPA and the disruption of
intracellular cholesterol homeostasis (Amini-Bavil-Olyaee et al.,
2013). In support of this mechanism, a cholesterol-binding agent
amphotericin B overcomes the inhibition of inﬂuenza A virus
infection by IFITM3 (Lin et al., 2013).
Not all enveloped viruses are inhibited by IFITM proteins.
Examples are lymphocytic choriomeningitis virus (LCMV), Lassa
virus (LASV), Machupo virus (MACH), human papillomavirus,
cytomegalovirus and adenovirus that are all resistant to IFITMs
(Brass et al., 2009; Warren et al., 2014). Among retroviruses,
murine leukemia virus (MLV) is relatively refractory to IFITMs,
the HIV-1 strain BH10 is inhibited, whereas another HIV-1 strain
IIIB exhibits resistance (Brass et al., 2009; Lu et al., 2011). In this
study, we examined a panel of HIV and SIV strains for their
sensitivity to IFITM inhibition. The results revealed various degrees
of inhibitions ranging from no inhibition for HIV-1A/G to 10-fold
inhibition for SIV of African green monkeys.
Results
IFITM proteins inhibit primate lentiviruses
In order to evaluate the susceptibility of different primate
lentiviruses to inhibition by IFITM1, 2 and 3, we selected the
following viruses for study, including three HIV-1 strains (the
laboratory adapted strain NL4-3, primary isolate YU-2 and the
circulating recombinant form A/G), one HIV-2 strain (HIV-2Rod),
ﬁve SIV strains from chimpanzees (SIVCPZ1.9), African green mon-
keys Chlorocebus sabaeus (SIVAGM-sab) and Chlorocebus tantalus
(SIVAGM-tan), rhesus macaques (SIVMAC-1A11) and sooty mangabeys
(SIVSMM). Since these viruses either use CXCR4 or CCR5 as the co-
receptor, we chose to infect the HIV indicator cell line TZM-bl that
expresses both CXCR4 and CCR5 and are thus susceptible to
infection by all these viruses. We ﬁrst transduced TZM-bl cells
with retroviral vectors expressing human IFITM1, 2 or 3 and
selected the stably transduced cell lines with puromycin. Ectopic
expression of IFITM1, 2 and 3 was conﬁrmed by western blotting
(Fig. 1A). We then challenged these TZM-bl cell lines with different
doses of HIV or SIV. Virus infection was monitored by measuring
luciferase activity that was expressed under the control of HIV-1
LTR promoter in TZM-bl cells. The data report the effect of IFITM
proteins on the early phase of HIV/SIV infection until viral Tat
protein is produced. Fig. 1B shows the luciferase activities of one
representative infection experiment that was performed with
different doses of viruses. The averages of three independent
experiments are summarized in Fig. 1C. The results showed that
SIVAGM-tan was inhibited the most, whereas infection of HIV-1,
SIVCPZ1.9 and SIVMAC were not profoundly affected by the three
human IFITM proteins. On the basis of the degrees of inhibition,
these primate lentiviruses are ranked as SIVAGM-tan4SIVAGM-sab,
SIVSMM, HIV-2Rod4HIV-1NL4-3, HIV-1YU-2, HIV-1A/G4SIVCPZ1.9 and
SIVMAC. The results also revealed that IFITM2 was the most
inhibitory, followed by IFITM3 and IFITM1.
IFITM2 strongly diminishes the entry of SIVAGM
Since IFITM proteins are known to inhibit virus entry (Feeley
et al., 2011; Lu et al., 2011), we asked whether the strong inhibition
of SIVAGM by IFITM2 is a result of impaired virus entry. To this aim,
we prepared the BlaM-Vpr-containing HIV and SIV particles, and
used these virions to infect IFITM-expressing TZM-bl cells. The
efﬁciency of virus entry was determined by measuring the
cleavage of CCF2 by BlaM-Vpr that enters the cytoplasm together
with viral cores. The results showed that the entry of HIV-1NL4-3
and SIVMAC into TZM-bl was marginally affected by IFITM1, 2 or 3
(Fig. 2). In contrast, the entry of SIVAGM-tan and SIVAGM-sab, to a
lesser extent SIVSMM, was strongly impaired by IFITM2 and IFITM3
(Fig. 2). This similar reduction in the entry of SIVAGM-tan and
SIVAGM-sab contrasts with a moderately stronger inhibition of
SIVAGM-tan infection by IFITM2 and 3 as shown in Fig. 1. This
difference suggests that SIVAGM-tan may be inhibited not only at
the entry step, but also at a downstream step until viral Tat is
produced, which is measured in the assays shown in Fig. 1.
We next asked whether the endogenous IFITM2 and 3 are able to
inhibit the entry of SIVAGM. We ﬁrst used shRNA to knock down
IFITM2 and 3 in TZM-bl cells (Fig. 3A). Both SIVAGM-tan and SIVAGM-sab
showed signiﬁcantly higher infection in the IFTIM2/3-knockdown
cells (Fig. 3B). Since the BlaM-Vpr containing SIVAGM-sab particles
generated much stronger signals in the entry assay than SIVAGM-tan
(Fig. 2), we further measured the effect of IFITM2/3-knockdown on
the entry of SIVAGM-sab. We also treated TZM-bl cells with IFNα2b to
increase the expression of endogenous IFITM2 and 3. The results
showed that IFNα2b reduced the entry of SIVAGM-sab by 2-fold and
this diminution was completely lost when IFITM2 and 3 were
depleted with shRNA (Fig. 3C and D). When the endogenous IFITM2
and 3 were knocked down in a human T cell line called C8166 that
constitutively express relatively high level of IFITM2, the entry of
SIVAGM-sab increased by approximately 50% (Fig. 3E–G). IFNα2b
treatment increased the expression of IFITM2 and 3, and results in
a 40% reduction in SIVAGM-sab entry. Depletion of IFITM2 and 3 under
IFNα2b treatment restored SIVAGM-sab entry to the control level
(Fig. 3E and F). We also observed that shRNA3 depleted IFITM2
much more efﬁciently compared to shRNA1 and shRNA2 (Fig. 3E),
which correlates with a moderately greater entry of SIVAGM-sab in
shRNA3-transdued C8166 cells than in shRNA1- or shRNA2-
transduced cells, albeit that this increase does not reach statistical
signiﬁcance (Fig. 3F and G). Together, these data indicate that
endogenous IFITM2 and 3 inhibit the entry of SIVAGM-sab.
Amphotericin B overcomes the inhibition of SIVAGM by IFITM2 and 3
It has been reported that amphotericin B prevents IFITM3 from
inhibiting inﬂuenza A virus through modulating membrane ﬂuidity
(Lin et al., 2013). We suspected that, if IFITM2 and 3 use the same
mechanism to inhibit SIVAGM and inﬂuenza A virus, then amphoter-
icin B should also rescue the infection of SIVAGM in IFITM2/3-
expressing cells. Indeed, when amphotericin B was added with
increasing doses, the infection of both SIVAGM-sab and SIVAGM-tan in
IFITM2 or IFITM3-expressing TZM-bl cells were restored to the level
of infection in control cells (Fig. 4A and B). HIV and SIV are known as
pH-independent viruses (McClure et al., 1988). Yet, the high sensi-
tivity of SIVAGM to IFITM2 and 3 inhibition raises the possibility that
this SIV may have become pH-dependent similar to the inﬂuenza A
virus. Contrary to this speculation, SIVAGM showed resistance to the
treatment of chloroquine or baﬁlomycin A1 both of which neutralize
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the pH in late endosomes and thus inhibit VSV G protein-mediated
pH-dependent virus entry (Fig. 4C). In further support of this
observation, the dynamin inhibitor dynasore moderately stimulated
the infection of SIVAGM (Fig. 4D), which suggests that, in contrast to
VSV that enters the cell via endocytosis and is thus sensitive to
dynasore treatment, the entry of SIVAGM is independent of endocy-
tosis. Together, these data indicate that IFITM2 and 3 exploit a
similar mechanism to inhibit viruses that enter cells via different
pathways.
SIVAGM is strongly restricted by IFITM3 of African green monkeys
We next asked whether SIVAGM is inhibited by IFITM proteins of
its natural host, African green monkeys. To answer this question, we
ﬁrst cloned IFITM1 and IFITM3 from the African green monkey
kidney cell lines called COS-7 and Vero. The agmIFITM1 exhibits a
much higher homology to macaque IFITM1 than to IFITM1 of humans
and chimpanzees (Fig. 5A). Similar to human IFITM1, agmIFITM1
exhibited no or only weak inhibition of HIV or SIV (Fig. 5B). Four
agmIFITM3 sequences were identiﬁed that differ at amino acid
positions 22 and 38 (Fig. 5A), no distinct agmIFITM2 sequence was
found. All four agmIFITM3 proteins inhibited HIV and SIV, with
SIVAGM-tan and SIVAGM-sab being the most inhibited (Fig. 5B). The
agmIFITM3 appears to elicit a much stronger inhibition than human
IFITM2 or IFITM3 (Fig. 1), which might have enabled agmIFITM3 to
suppress the infection of SIVAGM-tan and SIVAGM-sab to similar low
levels. The differences at amino acid positions 22 and 38 affected the
antiviral activity of IFITM3, agmIFITM3(I22H38) elicited the strongest
inhibition (Fig. 5B). Notably, the I22 residue is located within the
20-YEML-23 motif that directs the endocytosis of human IFITM3
(Chesarino et al., 2014; Jia et al., 2012; Jia et al., 2014). This may
explain the effect of M22I change on the antiviral function of
agmIFITM3. Since SIVAGM is potently inhibited by both human IFITM2
and agmIFITM3, it is likely that SIVAGM is much more susceptible to
IFITM restriction than other HIV and SIV strains regardless of the
species origin of the IFITM proteins.
Fig. 1. Effects of human IFITM1, 2 and 3 on infection of HIV and SIV. (A) TZM-bl cells were stably transduced with IFITM1, 2 or 3. Each IFITM has a Flag tag at the N-terminus.
Expression levels of IFITMs were determined by western blotting. Control represents cells that were transduced with empty retroviral vector pQCXIP. (B) Infection of TZM-bl
cell lines with HIV and SIV. Three HIV-1 strains (NL4-3, YU-2 and A/G), one HIV-2 strain (ROD), ﬁve SIV strains (CPZ1.9, SMM, MAC, AGM-tan and AGM-sab) were utilized in
infections. For each virus, series of ﬁve dilutions were tested. The virus amounts were chosen to generate infectivity in the linear range. Results shown represent the data of
three independent experiments. (C) Summary of three independent experiments at the infection dose of 33 for all tested viruses. The infection of the control TZM-bl cells is
arbitrarily set as 100% for each virus. Student's t-tests were performed to calculate the p-Values. The p-Values were presented as n (po0.05) or nn (po0.01).
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Fig. 2. Effects of human IFITM1, 2 and 3 on HIV and SIV entry. (A) The BlaM-Vpr-containing viruses were produced by transfecting HEK293T cells with pBlaM-Vpr DNA and
each of the HIV-1NL4-3, SIVAGM-tan, SIVAGM-sab, SIVMAC or SIVSMM DNA. These viruses were then used to infect TZM-bl cell lines that stably express IFITM1, 2 or 3. Virus entry
was determined by measuring the cleavage of CCF2 by BlaM-Vpr. (B) Results of three independent experiments are summarized. Virus entry of the control cells is arbitrarily
set as 100%. The p-Values were calculated and are presented as n (po0.05) or nn (po0.01).
J. Qian et al. / Virology 474 (2015) 10–18 13
Discussion
Viruses of different families are affected by IFITM proteins to
various degrees. Some viruses are strongly inhibited, examples are
inﬂuenza A viruses, ﬂaviviruses, Ebola viruses, and SARS corona-
viruses (Brass et al., 2009; Huang et al., 2011). Some are moder-
ately inhibited, such as vesicular stomatitis virus (Weidner et al.,
2010). Some are resistant to IFITM, including LCMV, MACH, LASV,
MLV, papillomavirus, cytomegalovirus and adenovirus (Brass et al.,
2009; Warren et al., 2014). Infection of human coronavirus OC43 is
even stimulated by IFITM2 or 3 (Zhao et al., 2014). Results of our
study showed that members of the same virus family such as
lentiviruses can be affected by IFITM proteins to markedly differ-
ent degrees that range from virtually no inhibition of SIVCPZ1.9 and
SIVMAC to a 10-fold restriction of SIVAGM by human IFITM2.
This observation appears to mirror the species-speciﬁc antiviral
activity that has been described for some host restriction factors
such as tetherin (Sauter et al., 2009). Human tetherin does not
inhibit HIV-1 because of the countering action of viral antagonist
Vpu, but it can block the release of SIVAGM. In a similar vein,
African green monkey tetherin potently inhibits HIV-1 owing to
the inability of HIV-1 Vpu to antagonize this monkey tetherin.
Fig. 3. Knockdown of endogenous IFITM2 and 3 increases the entry of SIVAGM-sab. (A) Knockdown of endogenous IFITM2 and 3 in TZM-bl cells. Three shRNA clones targeting
both IFITM2 and 3 were transduced into TZM-bl cells with or without IFNα-2b treatment (1000 U/ml, 16 h). Levels of endogenous IFITM2 and 3 were assessed by Western
blotting. (B) Effect of endogenous IFITM2 and 3 on the infection of SIVAGM-sab and SIVAGM-tan. IFITM2/3-knockdown TZM-bl cells were ﬁrst treated with IFNα-2b and then
infected with SIVAGM-sab or SIVAGM-tan. Viral infection was determined by measuring luciferase activities in the infected TZM-bl cells. Results of three independent
experiments are summarized in the bar graph with the infection of control TZM-bl cells arbitrarily set as 100%. (C) Effect of endogenous IFITM2 and 3 on SIVAGM-sab entry in
TZM-bl cells. BlaM-Vpr-containing SIVAGM-sab was used to infect the IFITM2/3-knockdown TZM-bl cells. Levels of virus entry were assessed by measuring the cleavage of
CCF2 using ﬂow cytometry. (D) The results of three independent virus entry experiments are summarized in the bar graph. (E) Knockdown of endogenous IFITM2 and IFITM3
in C8166 cells. The knockdown efﬁciency was examined by western blotting. (F and G) Effect of endogenous IFITM2 and 3 in C8166 cells on SIVAGM-sab entry. Details refer to
the legend to (C) and (D). The pValues were calculated and are presented as n (po0.05), nn (po0.01).
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However, our results showed that agmIFITM3 inhibits SIVAGM
more potently than human IFITM2 does, which suggests that
SIVAGM may have not been sufﬁciently pressured to escape from
the agmIFITM3 restriction. It is known that, in contrast to HIV and
SIV infections that cause AIDS, SIVAGM or SIVSMM infection of their
natural hosts is not pathogenic, which is at least partially attribu-
table to the rapid resolution of innate immune responses at the
acute infection stage and the lack of chronic immune activation
(Harris et al., 2010; Jacquelin et al., 2014). Therefore, after estab-
lishing the infection, SIVAGM or SIVSMM does not face the inhibition
by interferon and ISGs including IFITM proteins. In the absence of
selection by interferon, SIVAGM or SIVSMM may, in theory, develop
any level of sensitivity to IFITM proteins. It is therefore not a surprise
that SIVAGM is more restricted by IFITM3 compared to SIVSMM.
Human IFITM1, 2 and 3 often show different antiviral activities
as a result of their sequence divergence (Lu et al., 2011). Given the
closer homology between IFITM2 and 3 than to IFITM1, the antiviral
spectra of IFITM2 and 3 are better aligned than with IFITM1. This
trend is also seen in this study. IFITM1 is a weaker inhibitor of HIV
and SIV as compared to IFITM2 and 3.
We successfully cloned agmIFITM1 from COS-7 and Vero cells.
We also cloned four agmIFITM3 variants that differ at amino acid
positions 22 and 38. No distinct agmIFITM2 was found. Although
we cannot completely rule out the possibility that African green
Fig. 4. Effects of different agents on SIV infection. (A and B) Different doses of amphotericin B were used to treat TZM-bl cell lines that stably express IFITM2 and 3. The
control cell line was transduced with the empty pQCXIP retroviral vector. After one-hour pretreatment, cells were infected with SIVAGM-sab (A) or SIVAGM-tan (B). Virus
infection was monitored by measuring luciferase activity in TZM-bl cell lysates. (C and D) TZM-bl cells were treated with different doses of chloroquine or baﬁlomycin A1 to
neutralize the low pH in late endosomes and lysosomes. Cells were infected with SIVAGM-sab, SIVAGM-tan or VSV-G pseudotyped HIV-1NL4-3. Virus infection was determined by
measuring luciferase activity in TZM-bl cell lysates. (E) TZM-bl cells were treated with or without dynasore for 1 h followed by infection with SIVAGM-sab, SIVAGM-tan or VSV-G
pseudotyped HIV-1NL4-3. Levels of virus infection were monitored by measuring luciferase activity in TZM-bl cell lysates. Results shown are the averages of three independent
experiments. The p-Values were calculated and are presented as nn (po0.001).
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monkeys do not have an iﬁtm2 gene, no iﬁtm2 gene has been
described in the macaque genome except for two copies of iﬁtm3
genes. In other words, neither of the two copies of macaque iﬁtm3
genes has changed signiﬁcantly enough to become a distinct
iﬁtm2 gene as seen in humans and chimpanzees. It is possible
that in different primate hosts, the iﬁtm3 duplicate have under-
gone different levels of selection and as a result, exhibit different
levels of divergence. In some primates, like humans and chim-
panzees, one iﬁtm3 copy has accumulated enough changes to
become a distinct iﬁtm2 gene.
HIV and SIV are generally regarded as pH-independent viruses
as opposed to pH-dependent viruses such as inﬂuenza A viruses
that require low pH to accomplish viral membrane fusion (Earp
et al., 2005). We further conﬁrmed the pH-independent nature of
SIVAGM by showing its resistance to chloroquine and BafA1 both of
which neutralize the pH of late endosomes. We also observed that
SIVAGM infection is refractory to dynamin inhibitor dynasore,
which suggests that SIVAGM does not need endocytosis to enter
cells. Since both SIVAGM and inﬂuenza A viruses are potently
inhibited by IFITM proteins, it is evident that the routes of virus
entry do not necessarily determine the susceptibility of viruses to
IFITM restriction. Since the cholesterol-binding compound ampho-
tericin B counters the inhibition of SIVAGM and inﬂuenza A virus by
IFITMs, IFITM proteins likely utilize the same mechanism to
change the membrane ﬂuidity at the virus entry portals and thus
block viral membrane fusion.
In conclusion, our study demonstrates that IFITM proteins are
able to potently restrict the pH-independent virus such as SIVAGM
Fig. 5. Inhibition of HIV and SIV by IFITM1 and 3 of African green monkeys. (A) Sequence alignment of agmIFITM1 and 3. IFITM1 and IFITM3 cDNAs were cloned from African
green monkey kidney cell lines COS-7 and Vero. Their protein sequences are aligned with orthologs from macaques (mac), humans and chimpanzees (chimp). No distinct
IFITM2 was identiﬁed. Four agmIFITM3 sequences were found that vary at amino acid positions 22 and 38. (B) TZM-bl cells were stably transduced with agmIFITM1 and four
agmIFITM3 variants, then challenged with HIV-1NL4-3, HIV-1YU-2, HIV-1A/G, HIV-2ROD, SIVAGM-tan, SIVAGM-sab and SIVMAC. Results shown are the averages of three independent
experiments, with the infectivity in control cells arbitrarily set as 100% for each virus. The pValues were calculated and are presented as n (po0.05), nnn (po0.01).
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that does not require endocytosis for its entry. This observation
suggests that IFITM proteins do not strictly depend on its localiza-
tion to late endosomes for its antiviral action. Given the relative
closeness of SIVAGM to other IFITM-resistant SIV strains such as
SIVMAC, there exists an opportunity to identify the viral determi-
nant behind this IFITM resistance phenotype.
Materials and methods
Cell culture
The HEK293T, TZM-bl, COS-7 and Vero cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (Invitrogen) and penicillin/streptomycin
(Invitrogen). TZM-bl is an HeLa-derived cell line that expresses
CD4, CXCR4 and CCR5 and has a luciferase gene driven by HIV-1
LTR (Wei et al., 2002). C8166 were grown in RPMI1640 medium
supplemented with 10% fetal bovine serum and penicillin/strepto-
mycin. Transfection of HEK293T cells was performed with Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer's instructions.
Plasmids
HIV-1YU-2 (GenBank M93258), SIVCPZ1.910 (GenBank EF394356),
SIVAGM-tan (GenBank U58991), SIVAGM-sab (GenBank U04005), and
SIVMAC-1A11 (GeneBank M76764) proviral clones were obtained
through NIH AIDS Reagent Program. HIV-1A/G and HIV-2ROD clones
were generously provided by Mark Wainberg. SIVSMM-E543 (GenBank
U72748) clone was a gift from James Whitney. The human IFITM1,
2 and 3 cDNA sequences were cloned into the retroviral vector
pQCXIP as described previously (Lu et al., 2011). shRNA plasmids
targeting human iﬁtm2 and 3 genes were purchased from Sigma and
were used to produce lentiviral particles for transduction.
Virus production
To produce HIV-1 (NL4-3, YU2, A/G), HIV-2 (ROD) and SIV
(MAC, CPZ, AGM-sab, AGM-tan, SMM), HEK293T cells were trans-
fected with 6 μg of each viral DNA. For the production of BlaM-
Vpr-containing viruses, HEK293T cells were transfected with 6 μg
of viral plasmid DNA and 2 μg of plasmid DNA encoding the BlaM-
Vpr fusion protein. For the production of NL4-3 virus pseudotyped
by the VSV G protein, HEK293T cells were transfected with 6 μg of
NL4-3(env-) DNA and 0.2 μg of plasmid DNA encoding the G
protein of VSV. Forty-eight hours after transfection, culture super-
natants were collected and clariﬁed by centrifugation in the CS-6R
centrifuge (Beckman Coulter) at 3000 rpm for 30 min at 4 1C.
Viruses were aliquoted and stocked at 80 1C. The amounts of
viruses were determined by measuring the levels of viral reverse
transcriptase activity.
Generation of TZM-bl cells stably expressing IFITM1, IFITM2 or IFITM3
TZM-bl cells were infected with retroviral particles expressing
IFITM1, IFITM2 or IFITM3. Cells that stably express IFITMs were
selected with puromycin (2 μg/ml). For assessment of IFITM1,
IFITM2 and IFITM3 expression by western blot, TZM-bl cells were
lysed in the cytobuster buffer (Novagen #71009-4) containing
protease inhibitors (Roche #11 836 153 001) for 20 min on ice. Cell
lysate was resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), blotted onto PVDF (polyvinylidene
ﬂuoride) membrane (Roche). IFITMs proteins, containing a Flag
tag at their N-termini, were detected using monoclonal antibody
against the Flag tag (Sigma #F1804) and horseradish peroxidase
conjugated secondary antibodies (GE Healthcare).
Western blotting
Cells were lysed in the cytobuster buffer (Novagen) on ice for
20 min. After a brief spin, cell lysate was collected and mixed with
2 Laemmli buffer. Proteins were resolved by PAGE and trans-
ferred onto the PVDF membrane (Roche). Membranes were
blocked for 1 h at room temperature in 4% milk and incubated
with primary antibodies overnight at 4 1C. Anti-Flag antibody was
purchased from Sigma, anti-IFITM2 and anti-IFITM3 antibodies
from ProteinTech. After several washes in 1phosphate buffer
saline (PBS), membranes were further incubated with horseradish
peroxidase-conjugated secondary antibodies (GE Healthcare). Sig-
nals were detected by electrochemiluminescence (ECL) and visua-
lized by exposure to a Kodak ﬁlm.
shRNA silencing of IFITM proteins in TZM-bl and C8166 cells
TZM-bl or C8166 cells were transduced by lentiviral particles
allowing the expression of shRNAs against iﬁtm2 or 3 mRNAs.
Three shRNAs were able to deplete both IFITM2 and 3 proteins
(TRCN0000057502, TRCN0000118022, TRCN0000118025 from
Sigma) and were used in this study. Their sequences are:
shRNA1:CCGGCCTGTTCAACACCCTCTTCTTCTCGAGAAGAAGA-
GGGTGTTGAACAGGTTTTTG;
shRNA2:CCGGCCTGTTCAACACCCTCTTCATCTCGAGATGAAGAG-
GGTGTTGAACAGGTTTTTG;
shRNA3:CCGGGCTTCATAGCATTCGCCTACTCTCGAGAGTAGGCG-
AATGCTATGAAGCTTTTTG.
Twenty-four hours after transduction, cells were treated with
or without interferon α2b (IFNα2b) at 1000 U/ml for 24 h, followed
by infection with BlaM-Vpr-containing viruses to assess virus
entry efﬁcacy.
Entry assay
Viral fusion assay was performed by infecting TZM-bl or C8166
cells as described previously (Lu et al., 2011). In brief, cells were
exposed to BlaM-Vpr containing viruses and polybrene (5 μg/ml),
and spun for 45 min, 1800 rpm (CS-6R, Beckman Coulter) at 4 1C,
then incubated at 37 1C for 2 h. Cells were washed once with CO2
independent medium (Invitrogen), incubated with CCF2-AM con-
taining medium for 1 h at room temperature, washed once and
incubated with developing medium at room temperature for 16 h.
The following day, cells were washed 2 times in phosphate
buffered saline (containing 2% FBS), ﬁxed with 3.7% formaldehyde
and analyzed by ﬂow cytometry (BD, Fortessa) to monitor the
cleavage of CCF2-AM substrate by BlaM.
Cloning IFITM cDNA from African green monkey cells
COS-7 and Vero cells are both African green monkey kidney
cells. They were treated with IFNα2b for 16 h to induce IFITM
expression, followed by extraction of total cellular RNA with
Trizol (Invitrogen). Puriﬁed RNA was reverse transcribed and
ampliﬁed using a one-step RT-PCR system (Roche) with following
primers:
AGM_IFITM1_F1: 50–CAACAGGGGAAAGCAGGGCTC-30
AGM_IFITM1_F2: 50–CAACACTTCTTTCCCCAAAGCCAG-30
AGM_IFITM1_R1: 50–GTCATTGTGGACAGGTGTGTGGG-30
AGM_IFITM1_R2: 50–CTGTATCTAGGGGCAGGACCAAG-30
AGM_IFITM2/3_F1: 50–GGGAAAGGGAGGGCCCACTGAG-30
AGM_IFITM2/3_F2: 50–CCCACTAACCCGACCACCGCTG-30
AGM_IFITM2/3_R1: 50–GTGTGTGAGGATAAAGGGCTG-30
AGM_IFITM2/3_R2: 50–GGGCAGAGCTCCTGGCCTGAATG-30
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These primers were designed as follows. To clone African green
monkey IFITM1 (agmIFITM1), we aligned the 50 and 30 untrans-
lated regions (UTRs) of the iﬁtm1 genes of human, chimpanzee,
pongo, and macaque that are available in Genbank. Two forward
and two reverse primers are designed on the basis of the
conserved sequences. Primers for agmIFITM2/3 cloning were
similarly designed on the basis of the conserved UTRs of human
iﬁtm2 and 3, chimpanzee iﬁtm2 and 3, and two macaque iﬁtm3
genes. To amplify IFITM1 or IFITM2/3 cDNA, four RT-PCR reactions
were performed using the combinations of the 2 forward and
2 reverse primers. The ampliﬁed IFITM DNA fragments were
cloned into the pQCXIP retroviral vector (Clontech) between the
BamHI and EcoRI restriction sites and sequenced. A Flag tag was
added to the N-termini of the agmIFITM proteins and the agmI-
FITM cDNAs were cloned into pQCXIP for expression.
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